Yishai Ofran - Concepedia

Author

Yishai Ofran

Also Known As

Ishai Ofran, Kalman Filanovsky, M. Price, Ofran Yishay, R A Damoiseaux, Y Moshe, Y Ofran, Y. Ofran, Y., Ofran, Yishai Ofran

194

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Rambam Health Care Campus Shaare Zedek Medical Center Technion – Israel Institute of Technology Tel Aviv University Hadassah Medical Center

About

Yishai Ofran is an author at Rambam Health Care Campus specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	1.5K
2	Health Sciences	6	6	785
3	Arts	3	3	114
4	Engineering	1	1	75
5	Humanities	1	1	18

Yishai Ofran

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Blood Mixed-phenotype Acute LeukemiaPathologyMeasurable Residual DiseaseMyeloid NeoplasiaHematological Malignancy	2021	666
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission Andrew H. Wei, Hartmut Döhner, Christopher Pocock, New England Journal of Medicine	2020	403
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Michael Heuser, Yishai Ofran, Nicolas Boissel, Annals of Oncology Hematological MalignancyMedicineAdult PatientsMixed-phenotype Acute LeukemiaHematology	2020	266
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death Jessica K. Altman, Alfred Rademaker, Elizabeth H. Cull, Leukemia Research Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2013	131
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Blood	2019	97
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois, Leukemia Hematological MalignancyMedicineAcute Myeloid LeukemiaPharmacologyPharmacotherapy	2020	96
Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial Ilana Oren, Hannah Sprecher, Renato Finkelstein, American Journal of Infection Control Antimicrobial SusceptibilityAntibioticsAntimicrobial TherapyMicrobiologyInfection Control	2013	91
Patterns of Information-Seeking for Cancer on the Internet: An Analysis of Real World Data Yishai Ofran, Ora Paltiel, Dan Pelleg, PLoS ONE EngineeringFamily MembersInformation NeedsExploratory SearchInformation Seeking	2012	75
Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study Nizar Andria, Oryan Henig, Offer Kotler, Journal of Antimicrobial Chemotherapy	2015	68
Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study Drorit Merkel, Kalman Filanovsky, Anat Gafter‐Gvili, American Journal of Hematology	2012	67

Page 1